Vanda Pharmaceuticals Inc. (VNDA) experienced a setback in its quest for FDA approval of tradipitant for treating gastroparesis symptoms. The FDA issued a Complete Response Letter (CRL) requesting additional studies, leading to a 6.1% decline in Vanda’s share price. Despite the setback, Vanda continues to pursue approval for tradipitant, with ongoing development for motion sickness prevention.